Compare CGNX & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGNX | IMVT |
|---|---|---|
| Founded | 1981 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.3B |
| IPO Year | 1989 | N/A |
| Metric | CGNX | IMVT |
|---|---|---|
| Price | $36.41 | $25.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $46.64 | $25.29 |
| AVG Volume (30 Days) | 1.9M | ★ 1.9M |
| Earning Date | 02-11-2026 | 02-05-2026 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | ★ 27.63 | N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $971,705,000.00 | N/A |
| Revenue This Year | $9.46 | N/A |
| Revenue Next Year | $7.09 | N/A |
| P/E Ratio | $55.34 | ★ N/A |
| Revenue Growth | ★ 10.23 | N/A |
| 52 Week Low | $22.67 | $12.72 |
| 52 Week High | $49.76 | $27.69 |
| Indicator | CGNX | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 43.88 | 54.48 |
| Support Level | $35.93 | $24.95 |
| Resistance Level | $36.80 | $27.64 |
| Average True Range (ATR) | 0.95 | 1.13 |
| MACD | 0.13 | -0.22 |
| Stochastic Oscillator | 65.74 | 35.19 |
Cognex Corp provides machine vision products that help automate manufacturing processes. The firm's products include vision software, vision systems, vision sensors, and ID products. Vision software combines vision tools with a customer's cameras and peripheral equipment and can help with several vision tasks, including part location, identification, measurement, and robotic guidance. Vision systems combine a camera, processor, and vision software into a single package. Vision sensors deliver simple, low-cost solutions for common vision applications, such as checking the size of parts. ID products read codes that have been applied to items during the manufacturing process. Cognex generates the maximum proportion of its sales in the United States and Europe.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.